BRPI0607084A2 - uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto - Google Patents
uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e compostoInfo
- Publication number
- BRPI0607084A2 BRPI0607084A2 BRPI0607084-1A BRPI0607084A BRPI0607084A2 BR PI0607084 A2 BRPI0607084 A2 BR PI0607084A2 BR PI0607084 A BRPI0607084 A BR PI0607084A BR PI0607084 A2 BRPI0607084 A2 BR PI0607084A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- composition
- same
- deoxy
- deoxyprostaglandin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
USO DE UM COMPOSTO 11-DESóXI-PROSTAGLANDINA, COMPOSIçãO COMPREENDENDO O MESMO, E COMPOSTO. A presente invenção refere-se a um método e a uma composição para tratamento de um distúrbio do sistema nervoso central em um paciente mamífero, que compreende a administração de uma quantidade eficaz de um composto 11 -desóxi-prostaglandina a um paciente com necessidade deste. A invenção também fornece novo composto 11 -desóxi-prostaglandina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64700805P | 2005-01-27 | 2005-01-27 | |
PCT/JP2006/301704 WO2006080549A2 (en) | 2005-01-27 | 2006-01-26 | Method and composition for treating central nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607084A2 true BRPI0607084A2 (pt) | 2009-08-04 |
Family
ID=36740907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607084-1A BRPI0607084A2 (pt) | 2005-01-27 | 2006-01-26 | uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto |
Country Status (20)
Country | Link |
---|---|
US (2) | US8202909B2 (pt) |
EP (2) | EP1841433B1 (pt) |
JP (1) | JP5147404B2 (pt) |
KR (1) | KR101354771B1 (pt) |
CN (1) | CN101146541B (pt) |
AR (1) | AR055846A1 (pt) |
AU (1) | AU2006209072B2 (pt) |
BR (1) | BRPI0607084A2 (pt) |
CA (1) | CA2595898C (pt) |
DK (1) | DK1841433T3 (pt) |
ES (1) | ES2375082T3 (pt) |
HK (1) | HK1118716A1 (pt) |
IL (1) | IL184578A (pt) |
NO (1) | NO340257B1 (pt) |
NZ (1) | NZ556710A (pt) |
PL (1) | PL1841433T3 (pt) |
PT (1) | PT1841433E (pt) |
RU (1) | RU2440338C2 (pt) |
TW (1) | TWI384988B (pt) |
WO (1) | WO2006080549A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
US20080207759A1 (en) * | 2007-02-27 | 2008-08-28 | Sucampo Ag | Method for protecting mitochondria |
US8969324B2 (en) * | 2007-07-19 | 2015-03-03 | R-Tech Ueno, Ltd. | Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |
US8871752B2 (en) | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
US9084815B2 (en) | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
AU2010362494B2 (en) | 2010-10-15 | 2015-01-15 | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. | Processes for preparation of lubiprostone |
EP2667875A4 (en) * | 2011-01-24 | 2014-07-30 | Inceptum Res & Therapeutics Inc | COMPOSITIONS COMPRISING PROSTAGLANDIN FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
US20120270945A1 (en) * | 2011-04-19 | 2012-10-25 | Sucampo Ag | Method for modulating cytokine activity |
KR20140076551A (ko) * | 2011-08-05 | 2014-06-20 | 수캄포 아게 | 정신분열증의 치료 방법 |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
ES2731251T3 (es) * | 2014-10-21 | 2019-11-14 | Univ Illes Balears | Compuestos de 2-hidroxi-triacilglicerol para uso en el tratamiento de una enfermedad |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1120243A (en) | 1970-03-09 | 1968-07-17 | Samuelsson Bengt | Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof |
BE786215A (fr) | 1971-07-14 | 1973-01-15 | American Cyanamid Co | Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation |
ZA764727B (en) * | 1975-09-02 | 1977-07-27 | Upjohn Co | Prostanoic acid derivatives |
SU845774A3 (ru) | 1976-04-20 | 1981-07-07 | Фармиталия Карло Эрба С.П.А. (Фирма) | Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ |
US4131738A (en) * | 1977-07-05 | 1978-12-26 | The Upjohn Company | 6-Hydroxy-PGE1 compounds |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
DE69106744T2 (de) | 1990-02-26 | 1995-05-18 | R Tech Ueno Ltd | 15-Dehydroxy-16-oxoprostaglandine. |
CA2039420C (en) | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
JPH04187637A (ja) * | 1990-11-21 | 1992-07-06 | Ueno Seiyaku Oyo Kenkyusho:Kk | 記憶改善剤 |
JPH07113012B2 (ja) | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | 新規15−ケト−プロスタグランジン類 |
CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
DE69714698T2 (de) | 1996-06-10 | 2002-12-05 | Sucampo Ag | Endothelin-antagonisten |
AU739343B2 (en) * | 1997-11-28 | 2001-10-11 | Sucampo Ag | Endothelin antagonist |
JP3703004B2 (ja) | 1998-07-15 | 2005-10-05 | 小野薬品工業株式会社 | 5−チア−ω−置換フェニル−プロスタグランジンE誘導体 |
US7176238B1 (en) * | 1999-03-01 | 2007-02-13 | Nitromed Inc. | Nitrostated and nitrosylated prostaglandins, compositions and methods of use |
TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
KR100788226B1 (ko) * | 2000-03-24 | 2007-12-26 | 수캄포 아게 | 15-케토-프로스타글란딘 또는 이의 유도체를 포함하는세포자연사 억제 조성물 |
US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
CN1214794C (zh) * | 2003-09-08 | 2005-08-17 | 秦正红 | 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途 |
-
2006
- 2006-01-26 JP JP2007535160A patent/JP5147404B2/ja not_active Expired - Fee Related
- 2006-01-26 RU RU2007132081/04A patent/RU2440338C2/ru active
- 2006-01-26 PL PL06712847T patent/PL1841433T3/pl unknown
- 2006-01-26 ES ES06712847T patent/ES2375082T3/es active Active
- 2006-01-26 CA CA2595898A patent/CA2595898C/en not_active Expired - Fee Related
- 2006-01-26 AU AU2006209072A patent/AU2006209072B2/en not_active Ceased
- 2006-01-26 BR BRPI0607084-1A patent/BRPI0607084A2/pt not_active Application Discontinuation
- 2006-01-26 US US11/339,495 patent/US8202909B2/en active Active
- 2006-01-26 KR KR1020077019366A patent/KR101354771B1/ko active IP Right Grant
- 2006-01-26 EP EP06712847A patent/EP1841433B1/en active Active
- 2006-01-26 NZ NZ556710A patent/NZ556710A/en not_active IP Right Cessation
- 2006-01-26 EP EP11155203A patent/EP2332545A1/en not_active Withdrawn
- 2006-01-26 CN CN2006800094248A patent/CN101146541B/zh not_active Expired - Fee Related
- 2006-01-26 AR ARP060100290A patent/AR055846A1/es not_active Application Discontinuation
- 2006-01-26 PT PT06712847T patent/PT1841433E/pt unknown
- 2006-01-26 WO PCT/JP2006/301704 patent/WO2006080549A2/en active Application Filing
- 2006-01-26 TW TW095103028A patent/TWI384988B/zh not_active IP Right Cessation
- 2006-01-26 DK DK06712847.0T patent/DK1841433T3/da active
-
2007
- 2007-07-12 IL IL184578A patent/IL184578A/en active IP Right Grant
- 2007-08-24 NO NO20074332A patent/NO340257B1/no not_active IP Right Cessation
-
2008
- 2008-09-18 HK HK08110344.4A patent/HK1118716A1/xx not_active IP Right Cessation
-
2012
- 2012-05-14 US US13/470,377 patent/US20120225938A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200642690A (en) | 2006-12-16 |
NO20074332L (no) | 2007-10-17 |
PT1841433E (pt) | 2012-02-01 |
RU2440338C2 (ru) | 2012-01-20 |
CA2595898C (en) | 2015-04-28 |
EP1841433B1 (en) | 2011-11-30 |
US20060194880A1 (en) | 2006-08-31 |
JP2008528440A (ja) | 2008-07-31 |
US20120225938A1 (en) | 2012-09-06 |
AU2006209072B2 (en) | 2011-02-24 |
CA2595898A1 (en) | 2006-08-03 |
RU2007132081A (ru) | 2009-03-10 |
TWI384988B (zh) | 2013-02-11 |
WO2006080549A3 (en) | 2007-07-05 |
KR101354771B1 (ko) | 2014-01-22 |
EP1841433A2 (en) | 2007-10-10 |
CN101146541A (zh) | 2008-03-19 |
AR055846A1 (es) | 2007-09-12 |
AU2006209072A1 (en) | 2006-08-03 |
DK1841433T3 (da) | 2012-01-16 |
PL1841433T3 (pl) | 2012-07-31 |
WO2006080549A2 (en) | 2006-08-03 |
IL184578A (en) | 2015-02-26 |
JP5147404B2 (ja) | 2013-02-20 |
ES2375082T3 (es) | 2012-02-24 |
EP2332545A1 (en) | 2011-06-15 |
NO340257B1 (no) | 2017-03-27 |
NZ556710A (en) | 2010-08-27 |
US8202909B2 (en) | 2012-06-19 |
KR20070107065A (ko) | 2007-11-06 |
CN101146541B (zh) | 2012-04-11 |
HK1118716A1 (en) | 2009-02-20 |
IL184578A0 (en) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607084A2 (pt) | uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto | |
BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
ECSP11010975A (es) | Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales | |
BRPI0508098A (pt) | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
BRPI0906478B8 (pt) | anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende | |
BRPI0507645A (pt) | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico | |
CO6362020A2 (es) | Mutantes fgf21 y uso de los mismos | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BRPI0715396B8 (pt) | método de produção de uma composição para vacina | |
BRPI0606727A (pt) | terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue | |
BRPI0607330A2 (pt) | composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto | |
ECSP077401A (es) | Medicamentos que contienen compuestos de carbonilo y su uso | |
BRPI0509207A (pt) | moduladores canabinóides de tetraidro-indazol | |
BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ECSP099296A (es) | Inmuno-reguladores, preparaciones y composiciones que incluyen los inmuno-reguladores, pruebas para evaluar la actividad de los inmuno-reguladores y preparaciones y composiciones que incluyen los mismos y métodos | |
CL2008002247A1 (es) | Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros. | |
BRPI0612424A2 (pt) | composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas | |
BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |